secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001477932-24-002622
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants BioNexus Gene Lab 180-day extension to meet $1 bid price rule through Nov 4, 2024
--------------------------------------------------------------------------------

- Initial bid price deficiency notice received Nov 6, 2023; original 180-day cure period expired May 6, 2024.
- On May 8, 2024, Nasdaq granted additional 180-day extension to regain compliance, now due by Nov 4, 2024.
- To cure, closing bid price must be at least $1.00 for a minimum of 10 consecutive business days.
- If not cured, Nasdaq will delist; company may request hearing before Nasdaq Hearings Panel to stay delisting.
- Company states it will use reasonable efforts but cannot assure it will regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224002622/0001477932-24-002622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793224002622/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-24-002622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer